Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Travere Therapeutics, Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
14
2 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
RETROPHIN, INC. a former name
US, as the owner printed on each patent
2 publishedRetrophin, Inc. a former name
named as the applicant on its applications, in US
10 publishedTravere Therapeutics, Inc. its own name
named as the applicant on its applications, in US
2 publishedTravere Therapeutics, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 28, 2021 | 11,207,299 | Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases | Pharmaceuticals | Travere Therapeutics, Inc. |
| Dec 15, 2020 | 10,864,197 | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | Pharmaceuticals | RETROPHIN, INC. |
| Sep 10, 2019 | 10,407,447 | Pantothenate derivatives for the treatment of neurological disorders | Organic fine chemistry | RETROPHIN, INC. |
| Jul 30, 2019 | 10,364,263 | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders | Pharmaceuticals | RETROPHIN, INC. |
| Feb 20, 2018 | 9,896,464 | Pantothenate derivatives for the treatment of neurological disorders | Organic fine chemistry | RETROPHIN, INC. |
| Apr 25, 2017 | 9,629,862 | Pantothenate derivatives for the treatment of neurologic disorders | Pharmaceuticals | RETROPHIN, INC. |
| Nov 10, 2015 | 9,181,286 | Pantothenate derivatives for the treatment of neurologic disorders | Pharmaceuticals | RETROPHIN, INC. |
| May 5, 2015 | 9,023,793 | Intranasal carbetocin formulations and methods for the treatment of autism | Pharmaceuticals | RETROPHIN, INC. |
| Mar 18, 2014 | 8,673,883 | Pantothenate derivatives for the treatment of neurologic disorders | Pharmaceuticals | RETROPHIN, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 23, 2025 | 2025/0325523 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Pharmaceuticals | Travere Therapeutics, Inc. |
| Oct 23, 2025 | 2025/0325522 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Pharmaceuticals | Travere Therapeutics, Inc. |
| Jul 1, 2021 | 2021/0196688 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Pharmaceuticals | Retrophin, Inc. |
| Sep 10, 2020 | 2020/0281901 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Pharmaceuticals | Retrophin, Inc. · patent 10,864,197 granted from it |
| May 14, 2020 | 2020/0147050 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF TYPE IV COLLAGEN DISEASES | Pharmaceuticals | Retrophin, Inc. · patent 11,207,299 granted from it |
| Apr 23, 2020 | 2020/0121604 | SOLID FOSMETPANTOTENATE FORMULATIONS | Pharmaceuticals | Retrophin, Inc. |
| Nov 7, 2019 | 2019/0337971 | PANTETHEINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Pharmaceuticals | Retrophin, Inc. |
| Aug 29, 2019 | 2019/0262317 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Pharmaceuticals | Retrophin, Inc. |
| Dec 20, 2018 | 2018/0362564 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Pharmaceuticals | Retrophin, Inc. · patent 10,364,263 granted from it |
| Oct 11, 2018 | 2018/0291045 | PANTOTHENATE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Organic fine chemistry | Retrophin, Inc. · patent 10,407,447 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.